Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Apr 16, 2024 | Press Releases

Phio’s lead clinical product candidate, PH-762, is the subject of three new dermatological postersMARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary...

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

Apr 11, 2024 | Press Releases

MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing...

National Spotlight Features Phio’s Innovative RNAi Technology Platform

Apr 3, 2024 | Press Releases

-Program will be airing on PBS with Dennis Quaid in April -It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary...

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Apr 2, 2024 | Press Releases

– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments, extending Phio’s expertise in dermatological...

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Mar 21, 2024 | Press Releases

-Poster will be unveiled this week at the Immunotherapy Conference in MunichMARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene...